Trial reportEuropean journal of nuclear medicine and molecular imaging2026
Efficacy and evaluation of dose-response relationship of selective internal radiation therapy for the management of liver metastases in neuroendocrine neoplasia.
Trial report in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
purposeThe liver is the commonest site of metastases in neuroendocrine neoplasias (NENs) and is an independent predictor of poor outcome. Selective internal radiation therapy (SIRT) allows selective delivery of high dose radiation to liver tumours and has shown promise in the management of NENs. We determined the safety and efficacy of SIRT for inoperable liver metastases secondary to NENs. Dose-response and dose-toxicity relationship were assessed.
methodsA prospective, multicentre, phase 2 study was conducted. Primary outcomes were objective response rate (ORR) in the treated liver volume according to RECIST 1.1 and mRECIST criteria, incidence and severity of adverse events (AEs) at 6 months. Secondary outcomes were hepatic specific progression free survival, PFS, overall survival (OS), change in quality of life (QoL). Tumour dose-response relationship was derived retrospectively from post therapy yttrium-90 bremsstrahlung single photon emission computed tomography/CT for both the tumour and perfused normal liver.
results21 patients were analysed; majority had grade 2 NEN (67%) and were heavily pretreated, 76% having received prior systemic therapy including peptide receptor radiotherapy (33%). ORR by RECIST 1.1 and mRECIST were 14% and 45%, respectively. Median hepatic specific PFS, PFS and OS were 48.1, 13.3 and 49.9 months respectively. Only 3 patients experienced grade 3 AEs; 2 radiation-induced liver disease that resolved without sequelae and one arterial plug migration. No significant deterioration in QoL was observed following SIRT. Dosimetry analysis found a clear tumour dose/response relationship for 3-month ORR. Mean tumour dose in responders was 372 Gy versus 173 Gy in non-responders (p < 0.001). We identified a threshold tumour absorbed dose of 164 Gy for PFS 48.1months compared to 8.8months (HR 0.2, 95%CI 0.05-0.96. p = 0.03).
conclusionIn a prospective study of heavily pretreated patients, we have demonstrated clinical efficacy of SIRT for the management of liver metastases secondary to NENs. A tumour dose-response relationship was demonstrated and a threshold tumour dose for survival outcome. This work lends prospective evidence for personalised dosimetry in NENs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.